256 related articles for article (PubMed ID: 32406077)
1. Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Sun SS; Zhang DH; Shi Y; Lin CJ; Lin JY
J Clin Pharm Ther; 2020 Aug; 45(4):729-742. PubMed ID: 32406077
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
4. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Zhang S; Xie Q; Xie S; Chen J; Deng Q; Zhong L; Guo J; Yu Y
Pharmacotherapy; 2021 Sep; 41(9):781-791. PubMed ID: 34170566
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Li S; Yang H; Guo Y; Wei F; Yang X; Li D; Li M; Xu W; Li W; Sun L; Gao Y; Wang Y
Sci Rep; 2016 Sep; 6():33082. PubMed ID: 27605442
[TBL] [Abstract][Full Text] [Related]
7. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
8. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
9. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
10. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
11. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
12. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
[TBL] [Abstract][Full Text] [Related]
13. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Ye P; Yang S; Zhang W; Lv Q; Cheng Q; Mei M; Luo T; Liu L; Chen S; Li Q
Clin Ther; 2013 Feb; 35(2):180-9. PubMed ID: 23332451
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.
Xie H; Hu N; Pan T; Wu JC; Yu M; Wang DC
BMC Pharmacol Toxicol; 2023 Dec; 24(1):79. PubMed ID: 38098046
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
20. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]